Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.
On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.
Ibuprofen is the most commonly used and prescribed NSAID. It is a very common over-the-counter medication widely used as an analgesic, anti-inflammatory and antipyretic.
The use of ibuprofen and its enantiomer Dexibuprofen in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.
Due to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labour.
As ibuprofen is a widely used medication, the main therapeutic indications are:
Centre for Human Drug Research, Leiden, CL, Netherlands
Buddha Basnyat, MD, Kathmandu, Nepal
Seoul National University Hospital, Seoul, Korea, Republic of
Children's Medical Center of Dallas, Dallas, Texas, United States
White Mountain Research Center, Bishop, California, United States
UCSF Hypoxia Research Laboratory, San Francisco, California, United States
Helsinki University Central Hospital, Helsinki, Finland
Investigational Site Number 056001, Brussels, Belgium
Investigational Site Number 528001, Breda, Netherlands
Investigational Site Number 528002, Rotterdam, Netherlands
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.